Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 (mavoglurant) for reduction of cocaine use in patients with cocaine use disorder
2017-000736-33Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cocaine use disorder (CUD) comparing AFQ056 with Placebo (2 arms). Primary endpoint: Proportion of cocaine use days. Started Aug 2017; status: completed.
02
Drugs
mavoglurant
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on 2017-000736-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000736-33.